LCN2 and glioblastoma: The US clinical trial “MMP2, MMP9 and NGAL as Biomarkers for Glioblastoma (GBM) Biomarkers for the Prognosis of Glioblastoma (NCT01493219)” has been sponsored by University of Nebraska started since 2011.